Alzheimer disease is a large and growing public health problem that has prompted governments around the world, including in the United States, to develop national plans to address the disease.1 However, medications approved for the treatment of Alzheimer disease provide little symptomatic benefit, and the most recent approval by the US Food and Drug Administration occurred in 2003 (not including reformulations).
Bennett DA. Lack of Benefit With Idalopirdine for Alzheimer DiseaseAnother Therapeutic Failure in a Complex Disease Process. JAMA. 2018;319(2):123–125. doi:10.1001/jama.2017.19700
Customize your JAMA Network experience by selecting one or more topics from the list below.